Hospital
Meridian Hospitals Corporation
Meridian Hospitals Corporation was paid $4.72M by Medicaid between Jan 2018 and Jul 2018, across 162 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoMERIDIAN HOSPITALS CORPORATION
BRICK, NJ 08724
BRICK, NJ 08724
33aNPI1962409987assigned 07/05/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.72M
24GClaims64,397
24DCodes billed162
24AFirst – last monthJan 2018 – Jul 2018
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#65 of 93
Median peer was paid$30.60M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,397 | $4.72M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 4,651 | 4,430 | $1.51M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 2,924 | 2,698 | $1.09M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.1% | 1,651 | 1,585 | $337K |
| G0378 | Hospital observation service, per hour | 5.6% | 313 | 265 | $263K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.9% | 2,454 | 592 | $185K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.7% | 702 | 676 | $175K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.9% | 66 | 43 | $88K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 729 | 594 | $73K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.2% | 956 | 309 | $54K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 73 | 73 | $52K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.1% | 851 | 313 | $50K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 67 | 28 | $39K |
150 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,733 | $37K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 427 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,020 | $34K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 362 | $32K |
| 80053 | Comprehensive metabolic panel | <1% | 3,105 | $30K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 559 | $29K |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 583 | $27K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 164 | $24K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 161 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,090 | $17K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,059 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 157 | $15K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,669 | $15K |
| OP279 | <1% | 633 | $15K | |
| 84484 | <1% | 1,140 | $14K | |
| 97010 | <1% | 1,480 | $14K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 735 | $13K |
| 97162 | <1% | 163 | $13K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 626 | $13K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 276 | $13K |
| 81003 | <1% | 2,073 | $11K | |
| 71045 | Radiologic examination, chest; single view | <1% | 594 | $11K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 587 | $11K |
| 97161 | <1% | 112 | $10K | |
| OP379 | <1% | 144 | $10K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,190 | $9K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 105 | $9K |
| 97164 | <1% | 127 | $8K | |
| 85610 | <1% | 1,023 | $8K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 317 | $8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 506 | $8K |
| OP710 | <1% | 133 | $7K | |
| OP272 | <1% | 507 | $7K | |
| 76830 | Ultrasound, transvaginal | <1% | 148 | $7K |
| 36430 | <1% | 13 | $7K | |
| 93971 | <1% | 132 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 263 | $7K |
| 71250 | <1% | 44 | $7K | |
| 93970 | <1% | 51 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 100 | $7K |
| 76642 | <1% | 100 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 123 | $6K |
| OP259 | <1% | 3,265 | $6K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 93 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 97 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 84 | $5K |
| 93975 | <1% | 80 | $5K | |
| 80061 | Lipid panel | <1% | 250 | $5K |
| 85730 | <1% | 658 | $5K | |
| 87040 | <1% | 251 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 24 | $4K |
| 72110 | <1% | 128 | $4K | |
| 96376 | <1% | 191 | $4K | |
| 76536 | <1% | 57 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 71 | $4K |
| 87088 | <1% | 462 | $3K | |
| 85027 | <1% | 188 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 805 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 986 | $3K |
| 83880 | <1% | 162 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 190 | $3K |
| 80076 | <1% | 413 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 132 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 137 | $3K |
| 83690 | <1% | 843 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $2K |
| 74018 | <1% | 139 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 55 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 120 | $2K |
| 73610 | <1% | 196 | $2K | |
| 76775 | <1% | 42 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 16 | $2K |
| 73130 | <1% | 157 | $2K | |
| 73562 | <1% | 132 | $2K | |
| 72050 | <1% | 88 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 296 | $2K |
| 87070 | <1% | 810 | $2K | |
| 82607 | <1% | 69 | $2K | |
| 73630 | <1% | 215 | $2K | |
| 73110 | <1% | 128 | $2K | |
| 84439 | <1% | 115 | $2K | |
| 87186 | <1% | 116 | $2K | |
| 73030 | <1% | 166 | $2K | |
| 83735 | <1% | 303 | $2K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 240 | $1K |
| 76801 | <1% | 13 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 372 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 15 | $1K |
| 36591 | <1% | 47 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 180 | $1K |
| 84703 | <1% | 215 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 33 | $1K |
| 81025 | <1% | 420 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 194 | $1K |
| 86885 | <1% | 211 | $1K | |
| 87205 | <1% | 87 | $1K | |
| 85378 | <1% | 219 | $1K | |
| 83605 | <1% | 43 | $1K | |
| 83789 | <1% | 100 | $1K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 12 | $1K |
| 84702 | <1% | 187 | $1K | |
| 86900 | <1% | 261 | $994.61 | |
| 86901 | <1% | 263 | $914.27 | |
| 73140 | <1% | 107 | $808.59 | |
| 82248 | <1% | 131 | $805.99 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 815 | $734.59 |
| 97116 | <1% | 54 | $725.85 | |
| 85651 | <1% | 87 | $696.12 | |
| 90715 | <1% | 93 | $688.95 | |
| 86140 | <1% | 66 | $660.96 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $656.82 |
| 73564 | <1% | 44 | $633.76 | |
| 82746 | <1% | 13 | $633.47 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 76 | $621.97 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 76 | $619.36 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 95 | $600.89 |
| 73502 | <1% | 46 | $574.10 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 366 | $495.06 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 13 | $492.08 |
| 74022 | <1% | 29 | $421.35 | |
| 87999 | <1% | 228 | $374.20 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 30 | $338.24 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 29 | $338.24 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 20 | $304.00 |
| 82728 | <1% | 25 | $297.10 | |
| 86923 | <1% | 18 | $275.28 | |
| 72100 | <1% | 12 | $273.48 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 16 | $258.47 |
| 87147 | <1% | 122 | $253.50 | |
| 86617 | <1% | 18 | $209.42 | |
| 82150 | <1% | 139 | $204.74 | |
| 73080 | <1% | 31 | $184.19 | |
| 86308 | <1% | 92 | $174.10 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 89 | $157.87 |
| 82550 | <1% | 40 | $125.59 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 91 | $109.55 |
| 74019 | <1% | 12 | $83.25 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 103 | $83.10 |
| 83550 | <1% | 14 | $71.31 | |
| J2704 | Injection, propofol, 10 mg | <1% | 107 | $61.64 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $23.00 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 95 | $15.00 |
| 84100 | <1% | 14 | $14.60 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13 | $9.93 |
| 88313 | 0% | 12 | $0.00 | |
| 73590 | 0% | 13 | $0.00 | |
| 88342 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGANTNER, JOHN (SENIOR VP, FINANCE & CFO)
| Provider | Location | Paid |
|---|---|---|
| Meridian Hospitals Corporation | Neptune, NJ | $11.83M |
| Meridian Hospitals Corporation | Red Bank, NJ | $2.31M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.